Clinical trial · Observational
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
NCT06603506CI-TRIAL-00083002PENDORrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tumour and blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- tumour and blood collection
- description
- tumour and blood collection for realization ex vivo organoid models
- interventionNames
- Other: tumour and blood samples
Primary outcomes (1)
- measure
- Rate of establishment of exploitable tumor organoid lines
- timeFrame
- through study completion, an average of 3 years
- description
- Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient aged 18 years or more * Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment. * Patient with localized endometrial cancer, presenting: * A high-grade endometrioid histological type and/or * P53 mutation and/or * a non-endometrioid histological type regardless of P53 status. * Patient affiliated to a social security scheme * Information and signature of informed consent prior to any specific study procedure Exclusion Criteria: * Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin). * Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
References
Publications (1)
- DERIVEDGall GL, Cherifi F, Divoux J, Florent R, Christy F, Leconte A, San C, Devillers A, Desmartin G, Lecouflet L, Clarisse B, Ballesta S, Thorel L, Dubois B, Harter V, Rousseau N, Gaichies L, Martin-Francoise S, Le Brun JF, Dolivet E, Rouzier R, Jeanne C, Blanc-Fournier C, Figeac M, Leman R, Castera L, Poulain L, Weiswald LB, Joly F. The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors. BMC Cancer. 2025 Feb 11;25(1):244. doi: 10.1186/s12885-025-13590-6. PMID 39934735